Celebrating Success: Major Achievement in COMBACTE-CARE

Read more
combacte News Item

COMBACTE Scientific Papers 2022: Part 1

So far this year COMBACTE has published six scientific papers across the four projects. From the presence of C. difficile in potatoes to prosthetic joint infections due to S. aureus, the publications are filled to the brim with compelling results from our clinical studies. We've lined them up from newest to oldest below.

COMBACTE-NET, results from the ARTHR-IS trial

Preoperative and perioperative risk factors, and risk score development for prosthetic joint infection due to Staphylococcus aureus: a multinational matched case-control study

Objectives: To identify the preoperative and perioperative risk factors associated with post-surgical Staphylococcus aureus prosthetic joint infections (PJI) and to develop and validate risk-scoring systems, to allow a better identification of high-risk patients for more efficient targeted interventions.

COMBACTE-CDI

A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018

Objectives: To compare data on the populations with  infection (CDI) in hospitals vs the community across 12 European countries. There is a paucity of data on community-based CDI and how these compare with inpatient CDI.

Clostridioides difficile positivity rate and PCR ribotype distribution on retail potatoes in 12 European countries, January to June 2018

Objectives: While human-to-human transmission of  occurs often, other infection sources, including food, animals and environment, are under investigation. We present a large study on  in a food item in Europe, encompassing 12 European countries (Austria, France, Greece, Ireland, Italy, the Netherlands, Poland, Slovakia, Spain, Sweden, Romania and the United Kingdom).

  • These findings support recommendations for improving diagnosis in patients presenting with diarrhoea in the community, to guide good practice to limit the spread of CDI.

    https://doi.org/10.2807/1560-7917.ES.2022.27.26.2100704

COMBACTE-MAGNET

The antimicrobial resistance travel tool, an interactive evidence-based educational tool to limit antimicrobial resistance spread

Objectives: International travel has been recognized as a risk factor contributing to the spread of antimicrobial resistance (AMR). However, tools focused on AMR in the context of international travel and designed to guide decision making are limited. We aimed at developing an evidence-based educational tool targeting both healthcare professionals (HCPs) and international travellers to help prevent the spread of AMR.

Surveillance of antifungal resistance in candidemia fails to inform antifungal stewardship in European countries

Objectives: The increasing burden of candidemia and the emergence of resistance, especially among non-Candida albicans strains, represent a new threat for public health. We aimed to assess the status of surveillance and to identify publicly accessible resistance data in Candida spp blood isolates from surveillance systems and epidemiological studies in 28 European and 4 European Free Trade Association member states.

  • This easy-to-use, annually updated, freely accessible AMR travel tool, is the first of its kind to be developed. For HCPs, it can provide a valuable resource for teaching and a repository that facilitates a stepwise assessment of the risk of AMR spread and strengthen implementation of optimized infection control measures. Similarly, for travellers, the tool has the potential to raise awareness of AMR and outlines preventive measures that reduce the risk of AMR acquisition and spread.

    https://doi.org/10.1093/jtm/taac045

COMBACTE-CARE

Factors associated with recruitment success in the phase 2a study of aztreonam–avibactam development programme: a descriptive qualitative analysis among sites in Spain

Objectives: Successful clinical trials are subject to recruitment. Recently, the REJUVENATE trial, a prospective phase 2a open-label, single-arm interventional clinical trial conducted within the Innovative Medicines Initiative-supported Combatting Bacterial Resistance in Europe-Carbapenem Resistance project, was published, with 85% of the recruitment performed in Spain. We analysed the recruitment success in this trial by establishing a model of recruitment practice.

23/01/2024

“We Take Bigger Steps Together”

03/07/2023

COMBACTE's Last General Assembly

28/04/2023

COMBACTE Launches Last Magazine

COMBACTE launched its last magazine at ECCMID 2023 in Copenhagen. The magazine focuses on project’s impact, and features articles and interviews with ...